

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5629368

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
OCERA THERAPEUTICS		07/19/2019
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT	
<b>Street Address:</b>	60 WALL STREET	
<b>City:</b>	NEW YORK	
<b>State/Country:</b>	NEW YORK	
<b>Postal Code:</b>	10005	
<b>PROPERTY NUMBERS Total: 5</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	15751442	
<b>Application Number:</b>	16037655	
<b>Application Number:</b>	15133087	
<b>Application Number:</b>	15750009	
<b>Application Number:</b>	15349910	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	2136207848	
<b>Email:</b>	iprecordations@whitecase.com	
<b>Correspondent Name:</b>	JUSTINE LU/WHITE & CASE LLP	
<b>Address Line 1:</b>	555 SOUTH FLOWER STREET, 2700	
<b>Address Line 4:</b>	LOS ANGELES, CALIFORNIA 90071	
<b>ATTORNEY DOCKET NUMBER:</b>	1111779-2659-S216	
<b>NAME OF SUBMITTER:</b>	JUSTINE LU	
<b>SIGNATURE:</b>	/Justine Lu/	
<b>DATE SIGNED:</b>	07/22/2019	
<b>Total Attachments: 5</b>		
source=MNK - IP Supplement - Patents - Ocera Therapeutics, Inc. (Executed)#page1.tif		

source=MNK - IP Supplement - Patents - Ocera Therapeutics, Inc. (Executed)#page2.tif  
source=MNK - IP Supplement - Patents - Ocera Therapeutics, Inc. (Executed)#page3.tif  
source=MNK - IP Supplement - Patents - Ocera Therapeutics, Inc. (Executed)#page4.tif  
source=MNK - IP Supplement - Patents - Ocera Therapeutics, Inc. (Executed)#page5.tif

## **Notice of Grant of Security Interest in Intellectual Property**

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS, dated as of July 19, 2019 (this “**Agreement**”), made by Ocera Therapeutics, Inc., a Delaware corporation (the “**Pledgor**”), in favor of DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent (as defined below).

Reference is made to the U.S. Collateral Agreement dated as of March 19, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the “**U.S. Collateral Agreement**”), among Mallinckrodt International Finance S.A., a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124, boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (*R.C.S. Luxembourg*) under number B 172.865 (the “**Lux Borrower**”), MALLINCKRODT CB LLC (the “**Co-Borrower**”, and together with the Lux Borrower, the “**Borrowers**”), Mallinckrodt Holdings GmbH (as successor by merger to Mallinckrodt Finance GmbH) (the “**Swiss Finco**”), each other Subsidiary Loan Party listed on the signature pages hereof and each other Subsidiary Loan Party that becomes a party hereto after the date hereof and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the “**Collateral Agent**”) for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. **Grant of Security Interest.** As security for the payment and performance, as applicable, in full of its Secured Obligations, the Pledgor pursuant to the U.S. Collateral Agreement did, and hereby does, assign and pledge to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the “**IP Collateral**”):

all Patents of the United States of America, including those listed on Schedule I;

SECTION 3. **U.S. Collateral Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the U.S. Collateral Agreement. The Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the U.S. Collateral Agreement, the terms of the U.S. Collateral Agreement shall govern.


SECTION 4. *Counterparts*. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

SECTION 5. *Governing Law*. **THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

OCERA THERAPEUTICS, INC.

By:   
Name: John Einwalter  
Title: Vice President & Treasurer

DEUTSCHE BANK AG NEW YORK BRANCH,  
as Collateral Agent,

By:   
Name: Yumi Okabe  
Title: Vice President

By:   
Name: Alicia Schug  
Title: Vice President

*[Signature Page to Notice of Grant of Security Interest in Patents]*

Schedule I  
to Notice of Grant of Security Interest in Patents

*U.S. Patent Registrations*

N/A

*U.S. Patent Applications*

<b>Patent</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Owner</b>
TREATMENT AND PREVENTION OF NEURONAL CELL LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHE-NYLACETATE AND PHENYLBUTYRATE	15/751442	February 8, 2018	Ocera Thera- peutics, Inc.
L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF	16/037655	July 17, 2018	Ocera Thera- peutics, Inc.
FORMULATIONS OF L-ORNITHINE PHENYLACETATE	15/133087	April 19, 2016	Ocera Thera- peutics, Inc.
TREATMENT AND PREVENTION OF MUSCLE LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE	15/750009	February 2, 2018	Ocera Thera- peutics, Inc.
FORMULATIONS OF L-ORNITHINE PHENYLACETATE	15/349910	November 11, 2016	Ocera Thera- peutics, Inc.